Format

Send to

Choose Destination
Sci Rep. 2017 Aug 21;7(1):9022. doi: 10.1038/s41598-017-08422-y.

Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis.

Peng F1,2,3, Tang H1,4, Liu P4, Shen J1, Guan X5, Xie X2,3, Gao J2,3, Xiong L2,3, Jia L1, Chen J6,7, Peng C8,9.

Author information

1
School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
2
Chengdu University of Traditional Chinese Medicine, Chengdu, China.
3
State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China.
4
Department of Breast Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
5
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Pokfulam, Hong Kong.
6
School of Chinese Medicine, The University of Hong Kong, Pokfulam, Hong Kong. abchen@hku.hk.
7
Chengdu University of Traditional Chinese Medicine, Chengdu, China. abchen@hku.hk.
8
Chengdu University of Traditional Chinese Medicine, Chengdu, China. pengchengchengdu@126.com.
9
State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Sichuan Province and Ministry of Science and Technology, Chengdu, China. pengchengchengdu@126.com.

Abstract

Breast cancer is one of the most frightful causes of death among females worldwide. Accumulating evidence attached the importance of microRNAs negative regulation to tumorigenesis in breast cancer, suggesting novel cancer therapies targeting microRNAs modulation. Recent studies demonstrated that isoliquiritigenin could inhibit breast cancer cells proliferation and migration, but the underlying mechanism is still limited. In this study, the anti-cancer effects as well as the detailed mechanisms of isoliquiritigenin were explored. The results proved that isoliquiritigenin could negatively regulate breast cancer growth through the induction of apoptosis. We also verified the anti-cancer effect of isoliquiritigenin on migration and invasion, and identified highly expressed miR-374a as one of the main microRNAs down-regulated by isoliquiritigenin treatment in breast cancer. Further study displayed that isoliquiritigenin increased PTEN expression through the decrease of miR-374a expression to inhibit the aberrant Akt signaling. Our findings suggest isoliquiritigenin as a novel anti-cancer candidate significantly regulating miR-374a/PTEN/Akt axis in microRNA-based breast cancer therapies.

PMID:
28827662
PMCID:
PMC5567123
DOI:
10.1038/s41598-017-08422-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center